Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946243 · ClinicalTrials.gov registry record · Phase 4
The Feasibility of Florbetapir Quantitation
A Phase 4 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
NCT01946243 is a Phase 4 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 96 participants.
The verdict
NCT01946243, a Phase 4 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
Study Summary
The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation. The hypothesis is that the use of quantitative analysis will increase the accuracy of florbetapir F 18 scan interpretation.
Interventions
- DRUG Florbetapir F18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946243
The ClinicalTrials.gov registry entry for NCT01946243 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Florbetapir F18 is the first listed.
NCT01946243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01946243 about?
NCT01946243 is a clinical study titled "The Feasibility of Florbetapir Quantitation". The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation. The hypothesis is that the use of quantitative analysis will increase the accuracy of florbetapir F 18 scan interpretation.
What is the current status of trial NCT01946243?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2013-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01946243?
The interventions under investigation include: Florbetapir F18 (DRUG).
Who is sponsoring clinical trial NCT01946243?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.